Sharon Hanegraaf
Vice President, Drug Development & Strategy

Sharon has over 25 years of experience in international drug development spanning preclinical, clinical, drug development and product registration. Sharon specializes in regulatory strategy and CMC and has previously held regulatory affairs positions at pharmaceutical and biotechnology companies such as Prota Therapeutics, Hatchtech and Acrux.

Sharon has broad experience in various therapeutic indications, focusing on product commercialization in the US and other territories and has been involved in the successful approval of two drug products by the FDA, Axiron® and XeglyzeTM, originally developed in Australia.